Data to be presented at ACR meeting 

Copenhagen, Denmark; October 8, 2008 – Genmab A/S (OMX: GEN) announced today that data showing that rheumatoid arthritis patients who participated in  the ofatumumab (HuMax-CD20®) Phase II study achieved long lasting results at the 48 week follow up period.  The data will be presented in a poster session at the ACR/ARHP 2008 Annual Scientific Meeting in San Francisco, California on October 26, 2008.   The full abstract can be found by clicking this link, then clicking Advanced Search and typing "ofatumumab" in the Abstract Body field and pressing Enter.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site) of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any country.